Results 91 to 100 of about 5,323,391 (308)

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

Patient-Specific Modelling of Blood Coagulation

open access: yes, 2021
Blood coagulation represents one of the most studied processes in biomedical modelling. However, clinical applications of this modelling remain limited because of the complexity of this process and because of large inter-patient variation of the ...
Ratto N.
core  

Charge‐Reversed Lipid Nanoparticles Enable Encapsulation of Pt2L4 Nanocages for In vivo Anti‐Cancer Treatment

open access: yesAdvanced Materials, EarlyView.
Charge‐reversed lipid nanoparticles (revLNPs) enable efficient encapsulation and delivery of cationic Pt2L4 nanocages. Encapsulation preserves potent anticancer activity while improving circulation, reducing vascular leakage, and promoting favorable biodistribution in vivo.
Renzo A. Knol   +16 more
wiley   +1 more source

A Critical Call for Mechanistic Investigations of Metal‐Bacteria Interactions

open access: yesAdvanced Materials, EarlyView.
It is well established that the antibacterial properties of metals have tremendous importance for bioengineering applications. What is not as appreciated, however, is the reproducibility crisis in this field's vast literature. In this perspective, we highlight this reproducibility problem, discuss its sources, and suggest solutions towards focused ...
J. Rackwitz   +9 more
wiley   +1 more source

High prevalence of factor XIII deficiency and its association with bleeding in extracorporeal membrane oxygenation patients: an observational study from a prospectively compiled biobank

open access: yesResearch and Practice in Thrombosis and Haemostasis
Background: Coagulopathy is a major cause of death during extracorporeal membrane oxygenation (ECMO). Factor (F)XIII may play an important role in bleeding risk and represents a potential target for future therapies.
Andrea Kornfehl   +9 more
doaj   +1 more source

Biomass DNA: An Emerging Building Block for Advanced Materials

open access: yesAdvanced Materials, EarlyView.
Biomass DNA is rapidly emerging from its traditional role as a genetic blueprint to serve as a versatile abundant, highly programmable polymeric building block. This review highlights the transformation of macroscopic bulk biomass DNA into next generation of functional materials, spanning from dynamic hydrogels, sustainable bioplastics, and high ...
Yuwei Hu, Itamar Willner, Li Niu
wiley   +1 more source

Systemic coagulation parameters in mice after treatment with vascular targeting agents

open access: yesThrombosis Journal, 2005
Background Vascular targeting of malignant tumors has become a clinically validated new treatment approach with clear patient benefit. However clinical studies have also revealed that some types of vascular targeting agents (VTAs) are prone to ...
Gottstein Claudia   +2 more
doaj   +1 more source

Coagulation tests.

open access: yes, 2012
Coagulation tests.
Catherine Lombard (143878)   +7 more
core   +1 more source

A plasma medicine tool for accelerating blood coagulation [PDF]

open access: yes, 2019
Plasma medicine is an emerging field among the broad spectrum of the plasma science and technologies. In this contribution, we focus on the application of Cold Atmospheric Plasmas (CAPs) for accelerating blood coagulation. A review of the state of art on
De Masi, G., De Masi G
core   +1 more source

Magnetic Micro‐ and Nanorobots for Precision Thrombolysis: Design Strategies and Translational Challenges

open access: yesAdvanced Robotics Research, EarlyView.
Micro‐ and nanorobots for targeted thrombolysis. This perspective elaborates on the clinical indication of blood clot disorders and current limitations for treatment. As a novel, alternative solution, micro‐ and nanorobots can be used to treat and break down thrombi.
Joshua M. Mesfin   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy